1. ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma
- Author
-
Qing-Ling Fu, Song Guo Zheng, Xin Li, Xing-Liang Fan, Cheng-Lin Li, Y. B. Guo, Qiu-Ning Yu, Weiping Wen, Zi-Li Qin, Dong Chen, and W. P. Tan
- Subjects
Adult ,Male ,0301 basic medicine ,group 2 innate lymphoid cells ,Airway Diseases ,Immunology ,Young Adult ,03 medical and health sciences ,medicine ,Humans ,Immunology and Allergy ,Anti-Asthmatic Agents ,Lymphocyte Count ,STAT3 ,Glucocorticoids ,STAT5 ,Asthma ,STAT6 ,asthma patient ,biology ,business.industry ,Innate lymphoid cell ,JAK-STAT signaling pathway ,Immunoglobulin E ,Middle Aged ,medicine.disease ,inhibition ,Immunity, Innate ,Lymphocyte Subsets ,In vitro ,STAT signalling pathway ,Respiratory Function Tests ,STAT Transcription Factors ,Treatment Outcome ,030104 developmental biology ,Leukocytes, Mononuclear ,biology.protein ,Cytokines ,Original Article ,glucocorticoid ,Female ,ORIGINAL ARTICLES ,business ,Glucocorticoid ,Signal Transduction ,medicine.drug - Abstract
Background Group 2 innate lymphoid cells (ILC2s) were closely associated with asthma. However, there were no perspective studies about the effects of glucocorticoid on ILC2s in asthma patients. Our objective was to perform a perspective study and evaluate the ILC2 activity after glucocorticoid therapy in asthma patients. Methods The asthma and asthma with allergic rhinitis patients were treated with glucocorticoid for 3 months. The circulating ILC2 levels were evaluated. The effects of glucocorticoid on ILC2s and possible signalling pathways were investigated in vitro. Results The patients were well‐controlled, and the high ILC2 levels were significantly decreased at 1 and 3 months after treatment. Peripheral blood monocytes from allergic patients produced dramatic IL‐5, IL‐13 and IL‐9 in response to IL‐25, IL‐33 plus IL‐2, and glucocorticoid significantly decreased their levels. Moreover, ILC2s were identified to be the predominant source of IL‐5, IL‐13 and IL‐9, and glucocorticoid treatment was able to reverse their high levels. STAT3, STAT5, STAT6, JAK3 and MEK signalling pathways were proved to be involved in regulating ILC2 activity under the glucocorticoid treatment. Conclusion The data suggested that glucocorticoid administration could be effective in treating asthma by regulating ILC2s via MEK/JAK‐STAT signalling pathways. This provides a new understanding of glucocorticoid application in regard to allergic diseases.
- Published
- 2018
- Full Text
- View/download PDF